This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:food:aim_health:aging [01.11.2019] – [with additional studies] sallieq | home:food:aim_health:aging [02.09.2019] – [with additional studies] sallieq | ||
---|---|---|---|
Line 1: | Line 1: | ||
- | ====== | + | ====== |
Summary of research on aging and Olmesartan | Summary of research on aging and Olmesartan | ||
Line 7: | Line 7: | ||
===== with additional studies ===== | ===== with additional studies ===== | ||
- | |||
- | | ||
In conclusion, there is no robust signal for harm with olmesartan use. (({{pubmed> | In conclusion, there is no robust signal for harm with olmesartan use. (({{pubmed> | ||
Line 15: | Line 13: | ||
The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | ||
+ | |||
+ | | ||
The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed> | The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed> | ||
Line 20: | Line 20: | ||
Therapeutic and supratherapeutic OM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed> | Therapeutic and supratherapeutic OM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed> | ||
- | ==== general | + | ==== General |
- | Falls studies have determined that taking ≥ 4 drugs is associated with an increased incidence of falls, recurrent falls, and injurious falls. (({{pubmed> | + | When using off-label Olmesartan, patients are observed to need fewer other pharmaceutical preparations to maintain and improve health status. |
+ | These articles have identified holistic vitamin D supplementation with or without calcium is unlikely to be an effective primary prevention strategy for falls or fracture. There has also been high-quality evidence that vitamin D, daily or as a bolus, does not reduce the risk of cardiovascular events. (({{pubmed> | ||
==== Some of the documented protective effects of ARBs ==== | ==== Some of the documented protective effects of ARBs ==== | ||
| | ||
Line 109: | Line 110: | ||
=== Long term treatment === | === Long term treatment === | ||
- | Data suggest 40 & 80 mg olmesartan | + | |
// | // | ||
{{tag> | {{tag> | ||